The metabolism of arachidonic acid (AA) by either cyclooxygenase or lipoxygenase is believed to play an important role in carcinogenesis. Leukotriene (LT) D4 is a proinflammmatory mediator derived from AA through various enzymatic steps, and 5-lipoxygenase is an important factor in generating LTD4. We investigated LTD4 receptor (cysteinylLT1 receptor, CysLT1R) expression in renal cell carcinoma (RCC), as well as the effect of the CysLT1R antagonist on cell proliferation in the RCC cell line. CysLT1R expression was detected by immunohistochemistry and examined in RCC patients and normal kidney (NK) tissues. The effect of the CysLT1R antagonist on RCC cell growth was examined by MTT assay. Flow cytometry was used to determine whether or not the CysLT1R antagonist induced apoptosis. Initially, only slight CysLT1R expression was detected in NK tissues, and marked CysLT1R expression in RCC tissues. CysLT1R expression was higher in high-grade than in low-grade cancer. Furthermore, the CysLT1R antagonist caused marked inhibition of RCC cells in a concentration- and time-dependent manner through early apoptosis. To conclude, CysLT1R was induced in RCC and the results suggest that the CysLT1R antagonist may mediate the potent anti-proliferative effects of RCC cells. Thus, CysLT1R may become a new target therapy in the treatment of RCC.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Cysteine Leukotriene Receptor Antagonist-Montelukast-Treatment Improves Experimental Abdominal Aortic Aneurysms in Mice.
Cardiovasc Ther
January 2025
Institute of Cardiovascular Science, Translational Medicine Institute, Xi'an Jiaotong University Health Science Center, Xi'an, Shaanxi 710061, China.
Cysteinyl leukotrienes (LTs) and their receptors are involved in the pathogenesis of abdominal aortic aneurysms (AAAs). However, whether CysLT1 receptor antagonists such as montelukast can influence experimental nondissecting AAA remains unclear. Nondissecting AAAs were induced in C57BL/6J mice by transient aortic luminal infusion of porcine pancreatic elastase (PPE).
View Article and Find Full Text PDFCysteine Leukotriene Receptor Antagonist-Montelukast Effects on Diabetic Retinal Microvascular Endothelial Cells Curtail Autophagy.
Invest Ophthalmol Vis Sci
November 2024
Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, United States.
Purpose: Diabetic macular edema (DME) is the primary cause of vision impairment in diabetic retinopathy (DR) patients. A previous study has shown the efficacy of montelukast, a cysteinyl leukotriene receptor (CysLTR)1 antagonist, in a diabetic mouse model. This study aims to understand the CysLTR1 signaling in retinal endothelial cells and the impact of montelukast.
View Article and Find Full Text PDFCYSLTR1 antagonism displays potent anti-tumor effects in uveal melanoma.
Exp Eye Res
November 2024
Cancer Research Program, Research Institute of the McGill University Health Centre, Montreal, QC, Canada; The MUHC - McGill University Ocular Pathology & Translational Research Laboratory, Montreal, QC, Canada.
Article Synopsis
- * The study investigates the expression of the CYSLTR1 receptor in 31 human UM samples and shows that it is highly expressed in both primary and metastatic UM cells.
- * Blocking CYSLTR1 with the drug MK571 reduces UM cell growth and metabolic activity while increasing cell death, suggesting that targeting this receptor could be a promising treatment strategy for UM.
CysLT receptor-mediated NOX2 activation is required for IL-8 production in HMC-1 cells induced by Trichomonas vaginalis-derived secretory products.
Parasites Hosts Dis
August 2024
Department of Tropical Medicine and Institute of Tropical Medicine, Yonsei University College of Medicine, Seoul 03722, Korea.
Trichomoniasis is caused by a sexually transmitted flagellate protozoan parasite Trichomonas vaginalis. T. vaginalis-derived secretory products (TvSP) contain lipid mediators such as leukotriene B4 (LTB4) and various cysteinyl leukotrienes (CysLTs) which included LTC4, LTD4, and LTE4.
View Article and Find Full Text PDFPotential of Anti-Leukotriene Drugs as New Therapeutic Agents for Inhibiting Cholangiocarcinoma Progression.
Molecules
July 2024
Department of Gastroenterology and Metabolism, Graduate School of Medical Sciences, Nagoya City University, Nagoya 467-8601, Japan.
Article Synopsis
- - Cholangiocarcinoma (CCA) is a hard-to-diagnose cancer with limited treatment options, necessitating new targeted therapies; higher leukotriene levels in bile compared to serum were observed, alongside increased expression of the CysLT receptor in CCA tissue.
- - In laboratory tests, leukotriene D4, which activates the CysLT receptor, was found to promote cancer cell growth by triggering important signaling pathways (AKT and ERK1/2 phosphorylation).
- - The use of two existing anti-allergic drugs, zileuton and montelukast, inhibited cancer cell growth and movement, and their combined use further strengthened these effects, indicating potential for repurposing these drugs to treat CCA
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!